Roberts Glore & Co. Inc. IL Has $1.85 Million Stake in Bio-Techne Co. (NASDAQ:TECH)

Roberts Glore & Co. Inc. IL decreased its holdings in Bio-Techne Co. (NASDAQ:TECH) by 0.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 25,686 shares of the biotechnology company’s stock after selling 234 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in Bio-Techne were worth $1,850,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TECH. Empirical Finance LLC grew its stake in shares of Bio-Techne by 4.1% in the 3rd quarter. Empirical Finance LLC now owns 4,080 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 160 shares in the last quarter. Bradley Foster & Sargent Inc. CT grew its stake in shares of Bio-Techne by 1.5% in the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 10,799 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 160 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Bio-Techne by 46.4% in the 4th quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 168 shares in the last quarter. Verdence Capital Advisors LLC grew its stake in shares of Bio-Techne by 1.5% in the 4th quarter. Verdence Capital Advisors LLC now owns 11,967 shares of the biotechnology company’s stock valued at $862,000 after buying an additional 173 shares in the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Bio-Techne by 2.3% in the 4th quarter. Fifth Third Bancorp now owns 8,394 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 189 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Stock Up 1.5 %

Shares of Bio-Techne stock opened at $64.37 on Friday. Bio-Techne Co. has a 12-month low of $58.98 and a 12-month high of $85.57. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $10.18 billion, a P/E ratio of 65.02, a PEG ratio of 2.88 and a beta of 1.30. The stock has a 50 day moving average price of $70.61 and a two-hundred day moving average price of $72.67.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. Equities analysts expect that Bio-Techne Co. will post 1.67 earnings per share for the current year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were given a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.50%. Bio-Techne’s dividend payout ratio is 32.32%.

Analyst Upgrades and Downgrades

TECH has been the subject of several recent research reports. Royal Bank of Canada boosted their price target on Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 6th. Citigroup lowered their price target on Bio-Techne from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. KeyCorp upped their target price on Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Scotiabank upped their target price on Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 6th. Finally, Robert W. Baird cut Bio-Techne from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $82.14.

Insider Activity

In related news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the completion of the transaction, the chief executive officer now directly owns 39,004 shares in the company, valued at approximately $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Amy E. Herr sold 1,860 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the transaction, the director now owns 1,976 shares of the company’s stock, valued at $130,336.96. The trade was a 48.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is owned by company insiders.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.